Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
July 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
July 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
June 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
June 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
June 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
June 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
June 23, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
June 21, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
June 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
June 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)
June 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
June 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
June 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
June 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
May 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
May 17, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
May 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
May 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces First Quarter 2022 Financial Results
April 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
April 26, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
April 25, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
April 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
April 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
April 14, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
April 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
April 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
March 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
February 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.